Phaseline

Companies › O&D BioTech Group

O&D BioTech Group: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Mar 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
O&D-001 injection
Chimeric antigen receptor T cell targeting BCMA and GPRC5D
BCMA, GPRC5DPhase 1Relapsed or Refractory Multiple MyelomaMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07369895O&D-001 injectionPhase 1Relapsed or Refractory Multiple MyelomaOncologyMar 2028

Targets

BCMA (1) GPRC5D (1)

Companies with the same targets

Johnson & Johnson (Janssen) Regeneron Pharmaceuticals iCell Gene Therapeutics Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical AbbVie Chongqing Precision Biotech Poseida Therapeutics AstraZeneca Lakefront Biotherapeutics West Gracell Biotechnologies (Shanghai)

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.